$ADPT

LO FRANCIS sold $695K of ADPT

LO FRANCIS (Chief People Officer) sold 39,741 shares of Adaptive Biotechnologies Corp (ADPT) at $17.49 ($0.70M total) on 2026-06-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · LO FRANCIS
Published Jun 9, 2026, 12:29 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 9, 2026, 12:33 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ADPT
Neutral
high confidence
Mentioned
$ADPT
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ADPTNeutralLow
01

Why it matters

The only new fact is the officer’s open-market sale amount, share count, and confirmation of a pre-arranged 10b5-1 plan; no new company fundamentals are disclosed.

02

Market read

A routine 10b5-1 insider sale (~$695K) is disclosed; it is unlikely to materially change ADPT’s valuation absent other catalysts.

03

What to watch

The article lacks context on whether this is part of a larger selling cadence, and it provides no linkage to company-specific news.

Relevance 4/10Novelty 2/10Timing: Filed June 8; sale dated June 4

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Adaptive Biotechnologies (ADPT).

Company-level read

Ticker impact

$ADPTNeutralHigh confidence
Context

Adaptive Biotechnologies insider Form 4 shows Chief People Officer LO FRANCIS sold 39,741 shares for ~$695K under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any impact is likely short-lived and sentiment-driven.

Evidence & confidence

The disclosure is an open-market sale by an officer under a pre-arranged 10b5-1 plan, with no accompanying operational/regulatory/financial catalyst in the text.

Market effects

No clear read-across to biotech sector fundamentals from a single officer 10b5-1 sale.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with periods of weaker outlook; traders may watch for follow-on sales or other insider actions.

Key entities

  • Adaptive Biotechnologies Corp

    Subject of the SEC Form 4 insider transaction disclosure.

  • LO FRANCIS

    Chief People Officer who sold 39,741 ADPT shares.

  • 10b5-1 plan

    Pre-arranged plan indicated as the basis for the sale.

Related articles

$ADPTMed

Adaptive Biotechnologies Corp (ADPT): Results of Operations and Financial Condition

Adaptive Biotechnologies Corp (ADPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 adpt-ex99_1.htm EX-99.1 EX-99.1 EXHIBIT 99.1 Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results SEATTLE, Jul. 29, 2026 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnolo

$ADPTMedAI 9/10

Adaptive Biotech (ADPT) Reports 35% Revenue Growth Driven by Strong clonoSEQ Performance in Q1 2026

Adaptive Biotechnologies (NASDAQ:ADPT) reported Q1 2026 revenue of $70.9 million, up 35% year over year, driven by its MRD business, which generated 95% of revenue and rose 53%. clonoSEQ test volume increased 41% to 32,595. Net loss narrowed to $20.0 million; non-GAAP Adjusted EBITDA loss was $2.5 million. The company raised full-year 2026 MRD revenue guidance to $260–$270 million.